New Studies Conclude Xlear Kills and/or Deactivates SARS-CoV-2
30.11.2020 11:00:00 EET | Business Wire | Press release
New in vitro studies, led by renowned authority on respiratory diseases, conclude Xlear nasal spray is “an effective...and replicable means to deactivate SARS-CoV-2...to an undetectable amount of infectious virus.” This conclusion is “validated by two independent sets of experiments, performed by different labs, on different viral strains...” The Virucidal studies were independently funded.
“The Virucidal Studies shed important light on the role Xlear can play in helping combat the COVID-19 pandemic,” said Dr. Gustavo Ferrer, who is leading the research team.
State of scientific research:
Nasal sprays, such as Xlear, reduce viral load in the nose, which is vital in fighting COVID-19. Research shows COVID-19 primarily infects and spreads through the upper respiratory system. By reducing viral load in the nose, nasal sprays help limit the severity and transmission of SARS-CoV-2 (COVID-19). https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2768627.
Xlear’s components are antiviral—they block viral adhesion in the nose. See, for example, https://www.biorxiv.org/content/10.1101/2020.08.19.225854v1.full.pdf. This Univ. of Tennessee study on SARS-CoV-2 concluded: “antiviral nasal sprays...contribute reduce...viral load...slowing down disease progression...and transmission...”
Peer-reviewed case studies indicate Xlear helps in treating COVID-19: First-look trial at Larkin Community Hospital (Miami), determined: “symptomatic, COVID-19 patients, treated with [Xlear], as an adjunct to...[standard care],” showed “rapid clinical improvement and shorten[ed] time” to negative COVID-19 PCR tests. https://www.cureus.com/articles/43909-potential-role-of-xylitol-plus-grapefruit-seed-extract-nasal-spray-solution-in-covid-19-case-series.
Xlear has been used for over 20 years by millions of people worldwide without a single significant adverse incident report.
“Building on the existing data, these Virucidal Studies show Xlear is not just antiviral, it is virucidal (kills/deactivates SARS-CoV-2). This combination of antiviral and virucidal capabilities is an important one-two punch in fighting the virus,” said Nathan Jones, CEO of Xlear. “With the pandemic raging worldwide, we must use every tool we can to fight it. Failing that needlessly risks millions of lives. Weighing our 20-year safety record, against the risks of this deadly virus, it’s clear Xlear needs to be in widespread use,” Jones concluded.
Full study: https://www.biorxiv.org/content/10.1101/2020.11.23.394114v1.full
More information on Xlear: https://xlear.com/
About Dr. Gustavo Ferrer
Dr. Ferrer, MD FCCP, is an Associate Professor of Medicine and Founder of the Cleveland Clinic Florida Interstitial Lung Disease Clinic and the Aventura Hospital Pulmonary and Critical Care fellowship. He currently serves as President of Intensive Care Experts/Aventura Pulmonary Institute and previously served as United Nations University Director of Respiratory Research, Venezuela.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201130005291/en/
Contact information
Jeff Gulko
617.304.7339
jeff@thegulkogroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom